CLEU
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Clearleaf earns a Neutral rating with a 36.5 composite score and three-out-of-five conviction. The regulatory pillar leads at 50, supported by a 55 jurisdiction posture and an 80 enforcement subscore, despite a weak 25 cadence result. The market pillar contributes 40, reflecting the absence of an available quote rather than demonstrated trading strength. Editorial contributes 30, with no newsroom or brief activity to broaden investor visibility. Fundamentals rank last at 27: the exceptional gross-margin subscore of 100 is outweighed by a 15.2 revenue-growth subscore, zero operating-margin and market-cap tier scores, and a 15 cash-runway subscore. That mix anchors the shares firmly in the Neutral band.
Underlying performance remains stretched. Revenue contracted 34.8% year over year, while gross margin reached 63.9%, indicating attractive unit economics before operating costs. Those economics failed to carry through the income statement: operating margin was negative 520.8%, EBITDA was negative $5.0 million, and reported net income was zero. The 1.44 cash-burn ratio reinforces the stated stretched financial condition, while the roughly $3.5 million market capitalization leaves limited scale support. Regulatory visibility also remains thin. Primary regulatory filings show no latest filing date, no recorded events across either the 90-day or 180-day windows, and no enforcement hits. Institutional pricing feeds provide no available quote, licensed fundamentals data supports the weak operating profile, and CIN newsroom coverage records no recent newsroom or brief hits.
The clearest forward catalyst sits within the strongest pillar: regulatory. Clearleaf already benefits from a comparatively constructive jurisdiction score and a strong enforcement subscore, but filing cadence prevents that pillar from translating into a higher composite rating. A current primary regulatory filing that establishes consistent disclosure, clarifies operating continuity across Latin American activities, and provides updated financial reporting would directly address the 25 cadence subscore while improving the evidentiary base behind the Neutral assessment. Editorial activity and restored institutional pricing coverage would add visibility, but neither carries the same pillar weight or direct scoring leverage. The single most important signal to watch is the appearance of a current primary regulatory filing that resets disclosure cadence.
- IR email
- nza@clearagro.com
- IR page
- Investor relations
- CEO
- Lawrence Pratt
- CFO
- Alejandro Martínez Soto
- Website
- Company website
- Market cap
- $3.5M
- Enterprise value
- $-81.6M
- Price to book
- 0.00
- Price to sales
- 1.44
- EV / EBITDA
- 10.75
- Revenue (TTM)
- $2.4M
- Gross profit (TTM)
- $1.5M
- EBITDA
- $-5.0M
- Operating margin
- -520.8%
- Profit margin
- 0.0%
- Rev growth YoY
- -34.8%
- Return on equity
- -10.5%
- Return on assets
- -3.3%
- EPS (TTM)
- $-4079.38
- Shares outstanding
- 3.4M
- Insider ownership
- 1.5%
- Institutional ownership
- 1.4%
- Beta
- 1.84
- Full-time employees
- 63
- GICS sector
- Consumer Defensive
- GICS industry
- Education & Training Services
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for CLEU (CLEU)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for CLEU (CLEU), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CLEU are maintained by Cannabis Investor News and refreshed throughout the trading day.